Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

Results of a Phase I MSP-1 vaccine trial in healthy malaria-na¿ve adults in the US and in malaria-experienced adults in Kenya. The vaccine was well tolerated, although many vaccine recipients experienced pain, and several had local and systemic symptoms after vaccination; this is consistent with other AS01 adjuvanted vaccines.

Source: Malaria Journal - January 23, 2013 Category: Infectious Diseases Authors: Nekoye OtsyulaEvelina AngovElke Bergmann-LeitnerMargaret KoechFarhat KhanJason BennettLucas OtienoJames CummingsBen AndagaluDonna ToshJohn WaitumbiNancy RichieMeng ShiLori MillerWalter OtienoGodfrey OtienoLisa WareBrent HouseOlivier GodeauxMarie-Claude Du Source Type: research